ImmunityBio rises after responding to FDA concerns over advertising

Shares of biotech firm ImmunityBio IBRX.O rise 3% to $7.52 premarket

Co says it addressed FDA concerns on promotional materials for its bladder cancer drug Anktiva

Co says it removed a podcast from its website and asked third‑party platforms to take it down

Says a television advertisement cited by the FDA was never aired or shown to the public

FDA’s Office of Prescription Drug Promotion contacted co on March 13 over comments in a podcast by founder Patrick Soon‑Shiong and a TV advertisement - IBRX

Co's Anktiva is approved for use with BCG in adults who did not respond to prior therapy for a hard‑to‑treat form of bladder cancer

As of last close, stock up about three-fold YTD